Breaking News Instant updates and real-time market news.

OMED

OncoMed

$9.24

-0.35 (-3.65%)

08:48
11/29/16
11/29
08:48
11/29/16
08:48

OncoMed presents data for Anti-DLL4/VEGF

OncoMed Pharmaceuticals presented initial first-in-human data from its ongoing Phase 1 clinical trials of anti-DLL4/VEGF bispecific and anti-RSPO3 antibodies in two posters at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium being held in Munich, Germany. "In these first-in-human Phase 1 trials of our anti-DLL4/VEGF bispecific and anti-RSPO3 antibodies we have accomplished the primary goal of defining the safety profiles and establishing the single-agent doses for these agents. We have also observed initial evidence of anti-tumor activity in patients treated to date," said Jakob Dupont, M.D., Chief Medical Officer of OncoMed. "Dual blockade of DLL4 and VEGF has shown synergies preclinically, and in the clinic we are seeing evidence of single-agent activity with partial responses in ovarian and uterine cancers and stable disease in about one-third of the Phase 1 patients treated. We look forward to completing these trials and, in the near future, initiating Phase 1b studies with the anti-DLL4/VEGF bispecific in combination with standard of care in ovarian and colorectal cancers."

  • 29

    Nov

  • 29

    Nov

OMED OncoMed
$9.24

-0.35 (-3.65%)

06/06/16
BMOC
06/06/16
NO CHANGE
BMOC
OncoMed data positive, says BMO Capital
BMO Capital believes that data on three of OncoMed's drugs remove the risk of their development. The firm thinks that the data could cause the company's partners, Bayer and GlaxoSmithKline, to exercise options, yielding $1034M in non-dilutive financing for OncoMed.
06/06/16
PIPR
06/06/16
NO CHANGE
Target $29
PIPR
Overweight
Piper says confidence in OncoMed increased by ASCO updates
Piper Jaffray analyst Edward Tenthoff noted that OncoMed presented new Phase Ib data from vantictumab and ipafricept at the ASCO meeting, adding that he was "particularly impressed" by early ipafricept signal in ovarian cancer. The analyst, who contends that OncoMed has a "rich pipeline" of seven cancer biotherapeutics in the clinic, keeps an Overweight rating and $29 price target on the stock.
09/22/16
HCWC
09/22/16
INITIATION
Target $20
HCWC
Buy
OncoMed initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Shaunak Deepak started OncoMed Pharmaceuticals (OMED) with a Buy rating and $20 price target. The company is entering a "year of dramatic changes" with upcoming opt-in decisions for its lead drug candidates expected from partners Celgene (CELG), Bayer (BAYRY) and GlaxoSmithKline (GSK), Deepak tells investors in a research note. The analyst believes the partnerships could payoff with long-term benefits.
11/14/16
PIPR
11/14/16
NO CHANGE
PIPR
Piper sees Biotech rally continuing into 2017, lays out five to own
Piper Jaffray analyst Edward Tenthoff expects the rally in Biotechs, following "the trifecta" of a Trump Presidential election, Republican Congress sweep and defeat of Prop 61 in California, to continue into 2017. He recommends focusing on shares of Vertex (VRTX), Regeneron (REGN), Alnylam (ALNY), Exelixis (EXEL) and OncoMed (OMED). Tenthoff has a Neutral rating on Regeneron and Overweight ratings on the other four names.

TODAY'S FREE FLY STORIES

CYOU

Changyou.com

$25.06

-0.06 (-0.24%)

05:38
02/21/17
02/21
05:38
02/21/17
05:38
Earnings
Changyou.com reports Q4 EPS 75c, consensus 65c »

Reports Q4 revenue $131M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

FCX

Freeport McMoRan

$14.91

-0.16 (-1.06%)

05:37
02/21/17
02/21
05:37
02/21/17
05:37
Initiation
Freeport McMoRan initiated  »

Freeport McMoRan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SOHU

Sohu.com

$39.35

0.1 (0.25%)

05:36
02/21/17
02/21
05:36
02/21/17
05:36
Earnings
Sohu.com sees Q1 EPS ($1.80)-($1.55), consensus ($1.59) »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SEMG

SemGroup

$40.05

0.15 (0.38%)

05:34
02/21/17
02/21
05:34
02/21/17
05:34
Initiation
SemGroup initiated  »

SemGroup reinstated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

SOHU

Sohu.com

$39.35

0.1 (0.25%)

05:34
02/21/17
02/21
05:34
02/21/17
05:34
Earnings
Sohu.com reports Q4 EPS ($1.79), consensus ($2.08) »

Reports Q4 revenue $412M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

JELD

JELD-WEN Holding

$29.48

0.48 (1.66%)

05:33
02/21/17
02/21
05:33
02/21/17
05:33
Initiation
JELD-WEN Holding initiated  »

JELD-WEN Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REVG

REV Group

$27.59

0.37 (1.36%)

05:32
02/21/17
02/21
05:32
02/21/17
05:32
Initiation
REV Group initiated  »

REV Group initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REVG

REV Group

$27.59

0.37 (1.36%)

05:32
02/21/17
02/21
05:32
02/21/17
05:32
Initiation
REV Group initiated  »

REV Group initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAG

Jagged Peak Energy

$13.50

-0.08 (-0.59%)

05:30
02/21/17
02/21
05:30
02/21/17
05:30
Initiation
Jagged Peak Energy initiated  »

Jagged Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAG

Jagged Peak Energy

$13.50

-0.08 (-0.59%)

05:30
02/21/17
02/21
05:30
02/21/17
05:30
Initiation
Jagged Peak Energy initiated  »

Jagged Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAG

Jagged Peak Energy

$13.50

-0.08 (-0.59%)

05:29
02/21/17
02/21
05:29
02/21/17
05:29
Initiation
Jagged Peak Energy initiated  »

Jagged Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAG

Jagged Peak Energy

$13.50

-0.08 (-0.59%)

05:28
02/21/17
02/21
05:28
02/21/17
05:28
Initiation
Jagged Peak Energy initiated  »

Jagged Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAG

Jagged Peak Energy

$13.50

-0.08 (-0.59%)

05:28
02/21/17
02/21
05:28
02/21/17
05:28
Initiation
Jagged Peak Energy initiated  »

Jagged Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAG

Jagged Peak Energy

$13.50

-0.08 (-0.59%)

05:26
02/21/17
02/21
05:26
02/21/17
05:26
Initiation
Jagged Peak Energy initiated  »

Jagged Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFLYY

Air France-KLM

$6.83

0.29 (4.43%)

05:25
02/21/17
02/21
05:25
02/21/17
05:25
Upgrade
Air France-KLM rating change  »

Air France-KLM upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENGGY

Enagas

$12.34

-0.0699 (-0.56%)

05:24
02/21/17
02/21
05:24
02/21/17
05:24
Downgrade
Enagas rating change  »

Enagas downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRBP

Corbus Pharmaceuticals

$8.85

0.55 (6.63%)

04:55
02/21/17
02/21
04:55
02/21/17
04:55
Conference/Events
Cantor Fitzgerald health/pharma analysts hold analyst/industry conference call »

Analysts, along with Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

04:55
02/21/17
02/21
04:55
02/21/17
04:55
Conference/Events
CLSA automotive analyst holds an analyst/industry conference call »

Analyst Rosner, along…

AGR

AVANGRID

$40.91

0.13 (0.32%)

04:55
02/21/17
02/21
04:55
02/21/17
04:55
Conference/Events
AVANGRID to hold a financial update »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 28

    Feb

LHCG

LHC Group

$48.30

0.12 (0.25%)

04:55
02/21/17
02/21
04:55
02/21/17
04:55
Conference/Events
LHC Group management to meet with Oppenheimer »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 21

    Mar

HNI

HNI Corporation

$46.09

0.04 (0.09%)

04:55
02/21/17
02/21
04:55
02/21/17
04:55
Conference/Events
HNI Corporation management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

KN

Knowles

$19.42

0.14 (0.73%)

04:55
02/21/17
02/21
04:55
02/21/17
04:55
Conference/Events
Knowles management to meet with Roth Capital »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

04:55
02/21/17
02/21
04:55
02/21/17
04:55
General news
Breaking General news story  »

Philadelphia Federal…

04:55
02/21/17
02/21
04:55
02/21/17
04:55
General news
Breaking General news story  »

San Francisco Federal…

04:55
02/21/17
02/21
04:55
02/21/17
04:55
Conference/Events
UBS to hold a field trip »

UBS Telecom Trip to…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.